Super Capabilities are Now Within Your Reach. Experience the LightCycler® 96 Instrument's intuitive user interface and powerful analysis software. Innovative optics, cutting-edge thermal resolution and data reproducibility enable research breakthroughs. Find out how to become a scientific Superhero!
4 GETS YOU 10 Save 10% on any package of 4 conditional or constitutive knockouts in gene targeting projects. Scientists from the same organization can combine their orders to achieve discounts. Learn more.
Nature Reviews Drug Discovery is on Twitter
Advertisement
98 days from submission to publication*
Scientific Reports is an open access journal publishing technically sound research across all areas of the natural sciences.
Next-generation proteasome inhibitor approved in multiple myeloma doi:10.1038/nbt1112-1011 The US Food and Drug Administration in July approved Kyprolis (carfilzomib). Several other drugs are in clinical testing. Full Text
Calamitous HCV trial casts shadow over nucleoside drugs doi:10.1038/nbt1112-1015 Bristol-Myers Squibb's disastrous phase 2 combination trial of BMS-986094 and BMS-790052 has raised questions about the adequacy of prior safety trials and the potential pitfalls of accelerating drug development times. Full Text
Malaria vaccine gives disappointing results doi:10.1038/nature.2012.11785 Interim poor results of RTS,S vaccine trial in African children raise question marks over deployment. Full Text
An audience with: Garry Neil doi:10.1038/nrd3886 Garry Neil, acting CEO of TransCelerate, discusses the new precompetitive venture's aims to make clinical trials more efficient. Full Text
Turning lupus against cancer doi:10.1038/scibx.2012.1151 Researchers have found that a lupus-related autoantibody sensitizes cancer cells to DNA-damaging radiation and chemotherapy. Already proven safe in a clinical trial in SLE, it may be effective for BRCA-mutant cancers. Full Text
From the analyst's couch: Wet AMD market doi:10.1038/nrd3790 This analysis looks at the currently available therapies for age-related macular degeneration and at the emerging treatments that might offer more convenient and cost-effective options. Full Text
Alzheimer's Disease: JNK3 as new target in AD? doi:10.1038/nrd3876 Researchers have shown that Alzheimer’s disease is under tight control by JNK3, through a complex loop that drives the production of the neurotoxic peptide Aβ42. JNK3 deletion alleviated symptoms in a mouse model. Full Text
Metabolic disorders: New avenue to AMPK activation doi:10.1038/nrd3872 Researchers have identified a novel small-molecule AMPK activator that, through a mechanism involving NUR77, reduces blood glucose and alleviates insulin resistance in mouse models of diabetes. Full Text
G Protein-coupled receptors: Expanding the detection of GPCR activation doi:10.1038/nrd3874 A new high-throughput assay overcomes some limitations of previous assays, allowing the accurate detection of a wider range of GPCRs. Full Text
Structure and mechanism of a bacterial sodium-dependent dicarboxylate transporter doi:10.1038/nature11542 This study provides insights into the NaCT protein, including the identification of the substrate-binding motifs. This may aid the design of agents that target this protein to treat obesity, diabetes and cardiovascular diseases. Full Text
Immunomodulatory glycan LNFPIII alleviates hepatosteatosis and insulin resistance through direct and indirect control of metabolic pathways doi:10.1038/nm.2962 The administration of LNFPIII, an immunomodulatory glycan found in human milk and on parasitic helminths, improves glucose tolerance and insulin sensitivity in diet-induced obese mice. Full Text
MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles doi:10.1038/nrd3864 This Review focuses on the pharmacokinetic and pharmacodynamic properties of current miRNA inhibitor designs and their relevance to cardiovascular indications, and evaluates the opportunities and obstacles associated with this new therapeutic modality. Full Text
The spliceosome as a target of novel antitumour drugs doi:10.1038/nrd3823 This Review looks at drugs that target the alternative splicing of genes that are important for cancer progression, and at how an understanding of the molecular mechanisms of these may open new perspectives for novel antitumour therapies. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment